Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children107410.24287/j.1074LITERATURE REVIEWОБЗОР ЛИТЕРАТУРЫReview ArticleMolecular features of mature B-cell non-Hodgkin lymphomas in childrenМолекулярные особенности зрелоклеточных B-клеточных неходжкинских лимфом у детейhttps://orcid.org/0009-0004-0325-0272FilatovaL. S.ФилатоваЛ. С.
Russian Federation
volchcov.egor@yandex.ruhttps://orcid.org/0000-0002-2574-1636VolchkovE. V.ВолчковЕ. В.
Russian Federation
volchcov.egor@yandex.ruhttps://orcid.org/0000-0001-5354-7067SharlaiA. S.ШарлайА. С.
Russian Federation
volchcov.egor@yandex.ruhttps://orcid.org/0000-0003-3664-2876AbramovD. S.АбрамовД. С.
Russian Federation
volchcov.egor@yandex.ruhttps://orcid.org/0000-0001-5201-6475AbugovaY. G.АбуговаЮ. Г.
Russian Federation
volchcov.egor@yandex.ruhttps://orcid.org/0000-0002-4779-1896MyakovaN. V.МяковаН. В.
Russian Federation
volchcov.egor@yandex.ruResearch Institute of Molecular and Cellular Medicine, the Patrice Lumumba People's Friendship University of RussiaНаучно-исследовательский институт молекулярной и клеточной медицины ФГАОУ ВО «Российский университет дружбы народов им. Патриса Лумумбы»The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава РоссииThe S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center of the Department of Health of MoscowГБУЗ г. Москвы «Московский многопрофильный научно-клинический центр им. С.П. Боткина» Департамента здравоохранения г. Москвы140420262511751842701202606022026Copyright ©; 2026, «D. Rogachev NMRCPHOI»Copyright ©; 2026, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2026«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/1074

This article is a review of the current literature on the molecular and genetic features of mature B-cell non-Hodgkin lymphomas (B-NHL) in children. This group of lymphoproliferative neoplasms is characterized by relative similarity in morphological and immunophenotypic features while exhibiting pronounced heterogeneity at the molecular and genetic level. Recent studies have enabled the identification of distinct biological subtypes of B-NHL, which has significantly changed approaches to their diagnosis and treatment. Our review examines the classification features of B-NHL in children, as well as key molecular genetic abnormalities and oncogenic signaling pathways responsible for the development of this group of diseases. This article also highlights the need for pediatric-specific studies of B-NHL and the development of specialized diagnostic and therapeutic approaches is emphasized.

Настоящая статья представляет собой обзор современных литературных данных, посвященных молекулярно-генетическим особенностям зрелоклеточных В-клеточных неходжкинских лимфом (В-НХЛ) у детей. Данная группа лимфопролиферативных новообразований характеризуется относительной схожестью морфологических и иммунофенотипических признаков при выраженной гетерогенности на молекулярно-генетическом уровне. Современные исследования позволили выделить отдельные биологические подтипы В-НХЛ, что существенно изменило подходы к их диагностике и терапии. В настоящем обзоре рассматриваются особенности классификации В-НХЛ у детей, а также ключевые молекулярно-генетические нарушения и онкогенные сигнальные пути, ответственные за развитие данной группы нозологий. Кроме того, подчеркивается необходимость независимого от взрослой популяции изучения педиатрических В-НХЛ и разработки специализированных диагностических и терапевтических подходов.

pediatric lymphomasB-cell non-Hodgkin lymphomasBurkitt lymphomahigh-grade B-cell lymphomas11q aberrationdiffuse large B-cell lymphomaprimary mediastinal large B-cell lymphomaпедиатрические лимфомынеходжкинские В-клеточные лимфомылимфома Беркиттавысокоагрессивные В-клеточные лимфомыаберрация 11qдиффузная В-крупноклеточная лимфомапервичная медиастинальная В-крупноклеточная лимфомаHoldsworth F., Worku D., le Bretton A., Vella C., Walker E. A guide to Hodgkin and non-Hodgkin lymphomas: similarities and differences. Br J Nurs 2021;30(17):S16–22.Волчков Е.В., Ольшанская Ю.В., Мякова Н.В. Прогностические маркеры лимфобластной лимфомы. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2020;19(4):198–204. [Volchkov E.V., Olshanskaya Yu.V., Myakova N.V. Prognostic markers of lymphoblastic lymphoma. Pediatric Hematology/Oncology and Immunopathology 2025;19(4):198–204. (In Russ.)].Ceredig R., Rauch M., Balciunaite G., RolinkIncreasing A.G. Flt3L availability alters composition of a novel bone marrow lymphoid progenitor compartment. Blood 2006;108(4):1216–22.Von Muenchow L., Alberti-Servera L., Klein F., Capoferri G., Finke D., Ceredig R. Permissive roles of cytokines interleukin-7 and Flt3 ligand in mouse B-cell lineage commitment. Proc Natl Acad Sci U S A 2016;113(50)E8122–30.Medvedovic J., Ebert A, Tagoh H., Busslinger M. Pax5: a master regulator of b cell development and leukemogenesis. Adv Immunol 2011;111:179–206.Sanz E., Muñoz-A N., Monserrat J., Van-Den-Rym A., Escoll P., Ranz I., Alvarez-Mon M., de-la-Hera A. Ordering human CD34+CD10–CD19+ pre/pro-B-cell and CD19-common lymphoid progenitor stages in two pro-B-cell development pathways. Proc Natl Acad Sci U S A 2010;107(13):5925–30.Melchers F. The pre-B-cell receptor: selector of fitting immunoglobulin heavy chains for the B-cell repertoire. Nat Rev Immunol 2005;5(7)578–84.Jaffe D.B., Shahi P., Adams B.A., Chrisman A.M., Finnegan P.M., Raman N. Functional antibodies exhibit light chain coherence. Nature 2022;611(7935):352–7.Noviski M., Mueller J.L., Satterthwaite A., Garrett-Sinha L.A., Brombacher F., Zikherman J. IgM and IgD B cell receptors differentially respond to endogenous antigens and control B cell fate. eLife 2018;7:e35074.Муто Т., Okazaki I.-mi, Yamada S., Tanaka Y., Kinoshita K., Muramatsu M. Negative regulation of activation-induced cytidine deaminase in B cells. Proc Natl Acad Sci 2006;103(8):2752–7.Meyer S.N., Koul S., Pasqualucci L. Mouse models of germinal center derived B-cell lymphomas. Front Immunol 2021;12.Wenzinger C., Williams E., Gru A.A. Updates in the pathology of precursor lymphoid neoplasms in the revised fourth edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Curr Hematol Malig Rep 2018;13(4):275–88.Alaggio R., Amador C., Anagnostopoulos I., Attygalle A.D., de Oliveira Araujo I.B., Berti E. et al. The 5th ed. of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022;36(7): 1720–48.Campo E., Jaffe E.S., Cook J.R., Quintanilla-Martinez L., Swerdlow S.H., Anderson K.C. et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022;140(11):1229–53.Naing P.T., Kaur A., Lynch D.T. Burkitt lymphoma. StatPearls. Treasure Island (FL): StatPearls Publishing, 2025.Farnworth-McHugh S., Barth N., Melville L., Paterson M., Lynch C., Holland P. et al. Potential oncogenic effect of the MERTK-dependent apoptotic-cell clearance pathway in starry-sky B-cell lymphoma. Front Immunol 2020;11:1759.Giulino-Roth L., Wang K., MacDonald T.Y., Mathew S., Tam Y., Cronin M.T. et al. Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood 2012;120(26):5181–4.Kelemen K., Braziel R.M., Gatter K., Bakke T.C., Olson S., Fan G. Immunophenotypic variations of Burkitt lymphoma. Am J Clin Pathol 2010;134(1):127–38.Jiménez C., Garrote-de-Barros A., López-Portugués C., Hernández-Sánchez M., Díez P. Characterization of human B cell hematological malignancies using protein-based approaches. Int J Mol Sci 2024;25(9):4644.Dang C.V. MYC on the path to cancer. Cell 2012;149(1):22–35.Cai Q., Medeiros L.J., Xu X., Young K.H. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. Oncotarget 2015;6(36):38591–616.Jha R.K., Kouzine F., Levens D. MYC function and regulation in physiological perspective. Front Cell Dev Biol 2023;11.t(8;14)(q24;q32) IGH/MYC< br> t(2;8)(p12;q24) IGK/MYC< br> t(8;22)(q24;q11) IGL/MYC [Electronic resource]. URL: https://atlas-geneticsoncology.org/haematological/ 1050/t(8;14)(q24;q32)-igh-myc-br-t(2;8) (p12;q24)-igk-myc-br-t(8;22)(q24;q11)-igl-myc (accessed: 16.11.2025).Panea R.I., Love C.L., Shingleton J.R., Reddy A., Bailey J.A., Moormann A.M. et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood 2019;134(19):1598–607.Grygalewicz B., Szafron L.M., Szafron L.A., Woroniecka R., Parada J., Ott G. et al. Cytogenomic and clinicopathologic comparison of MYC-positive and MYC-negative high-grade B-cell lymphoma with 11q aberration in the context of other aggressive lymphomas with MYC rearrangement. Mod Pathol 2025;38(8):100774.Barisic D., Chin C.R., Meydan C., Teater M., Tsialta I., Mlynarczyk C. et al. ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. Cancer Cell 2024;42(4):583–604.e11.Huang Y.-H., Cai K., Xu P.-P., Wang L., Huang C.-X., Fang Y. et al. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. Signal Transduct Target Ther 2021;6(1):101.Al-Khreisat M.J., Hayati Ismail N., Tabnjh A., Arbaeyah Hussain F., Aziz Mohamed Yusoff A., Farid Johan M., Asiful Islam M. Worldwide prevalence of Epstein–Barr virus in patients with Burkitt lymphoma: a systematic review and meta-analysis. Diagnostics (Basel) 2023;13(12):2068.Karimi M., Mousavi S.A. Burkitt’s lymphoma with multi-organ involvement. Int J Surg Case Rep 2024;125:110619.Yanchus C., Drucker K.L., Kollmeyer T.M., Tsai R., Winick-Ng W., Liang M. et al. A noncoding single-nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation. Science 2022;378(6615): 68–78.Волчков Е.В., Абугова Ю.Г., Бренинг К.Р., Абрамов Д.С., Фоминых В.В., Сенченко М.А. и др. Прогностическое значение статуса гена TP53 у детей с лимфомой Беркитта на протоколе В-НХЛ-2010М. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2024;23(1):56–62. [Volchkov E.V., Abugova Yu.G., Brenning K.R., Abramov D.S., Fominykh V.V., Senchenko M.A. et al. The prognostic value of TP53 mutational status in children with Burkitt lymphoma treated according to the B-NHL-2010M protocol. Pediatric Hematology/Oncology and Immunopathology 2024;23(1):56–62.Lindström M.S., Klangby U., Wiman K.G. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene 2001;20(17):2171–7.Burkhardt B., Michgehl U., Rohde J., Erdmann T., Berning P., Reutter K. et al. Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. Nat Commun 2022;13(1):3881.Joerger A.C., Stiewe T., Soussi T. TP53: the unluckiest of genes? Cell Death Differ 2025;32(2):219–24.Cairo M.S. TP53 binding domain mutations are bad news in Burkitt lymphoma. Haematologica 2024;109(9):2775–7.Glaviano A., Foo A.S.C., Lam H.Y., Yap K.C.H., Jacot W., Jones R.H. et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer 2023;22(1):138.Song M. S., Salmena L., Pandolfi P. P. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012;13(5):283–96.Gutiérrez-Hoya A., Soto-Cruz I. Role of the JAK/STAT pathway in cervical cancer: its relationship with HPV E6/E7 oncoproteins. Cells 2020;9(10):2297.Grondona P., Bucher P., Schulze-Osthoff K., Hailfinger S., Schmitt A. NF-kB Activation in Lymphoid malignancies: genetics, signaling, and targeted therapy. Biomedicines 2018;6(2):38.Corinaldesi C., Holmes A.B., Martire G., Tosato A., Rizzato D., Lovisa F. Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance. Leukemia 2025;39(1): 189–98.Love C., Sun Z., Jima D., Li G., Zhang J., Miles R. et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012;44(12):1321–5.Prochorec-Sobieszek M. The WHO 2016 classification of B-cell lymphomas – important changes. Hematol Clin Pract 2016;7(4): 261–72.Swerdlow S.H., Campo E., Pileri S.A., Lee Harris N., Stein H., Siebert R. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127(20):2375–90.Campo E., Swerdlow S.H., Harris N.L., Pileri S., Stein H., Jaffe E.S. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117(19):5019–32.Zajdel M., Szafron Ł.M., Paziewska A., Rymkiewicz G., Dąbrowska M., Bystydzieński Z. et al. microRNA profile of high-grade B-cell lymphoma with 11q aberration. Int J Mol Sci 2024;26(1):285.Gonzalez-Farre B., Ramis-Zaldivar J.E., Salmeron-Villalobos J., Balagué O., Celis V., Verdu-Amoros J. et al. Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma. Haematologica 2019;104(9):1822–9.Salaverria I., Martin-Guerrero I., Wagener R., Kreuz M., Kohler C.W., Richter J. et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood 2014;123(8):1187–98.Yamada S., Oka Y., Muramatsu M., Hashimoto Y. High-grade B-cell lymphoma with 11q aberrations: a single-center study. J Clin Exp Hematop 2023;63(2):121–31.Grygalewicz B., Woroniecka R., Rymkiewicz G., Rygier J., Borkowska K., Kotyl A. et al. The 11q-gain/loss aberration occurs recurrently in MYC-negative burkitt-like lymphoma with 11q aberration, as well as MYC-positive Burkitt lymphoma and MYC-positive high-grade B-Cell lymphoma, NOS. Am J Clin Pathol 2018;149(1):17–28.Wagener R., Seufert J., Raimondi F., Bens S., Kleinheinz K., Nagel I. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. Blood 2019;133(9):962–6.Grygalewicz B., Woroniecka R., Rymkiewicz G., Rygier J., Borkowska K., Kotyl A. The 11q-gain/loss aberration occurs recurrently in MYC-negative Burkitt-like lymphoma with 11q aberration, as well as MYC-positive Burkitt lymphoma and MYC-positive high-grade B-cell lymphoma, NOS. Am J Clin Pathol 2017;149(1):17–28.Jeon W., Kwon Koh Y., Kang S., Kim H., Koh K.-N., Joon Im H. Clinical characteristics and treatment outcomes of children and adolescents with aggressive mature B-cell lymphoma: a single-center analysis. Blood Res 2022;57(1): 41–50.Olszewski A.J., Kurt H., Evens A.M. Defining and treating high-grade B-cell lymphoma, NOS. Blood 2022;140(9):943–54.Ok C.Y., Medeiros L.J. High-grade B-cell lymphoma: a term re-purposed in the revised WHO classification. Pathology 2020;52(1):68–77.Lone W., Bi C., Lone W., Zhang W., Kedwaii A., Heavican T. et al. High-grade B-cell lymphoma not otherwise specified, with diffuse large B-cell lymphoma gene expression signatures: genomic analysis and potential therapeutics. Am J Hematol 2025;100(1):10–22.Liu T., Zhang L., Joo D., Sun S.-C. NF-kB signaling in inflammation. Signal Transduct Target Ther 2017;(2):17023.Palkowitsch L., Marienfeld U., Brunner C., Eitelhuber A., Krappmann D., Marienfeld R.B. The Ca2+-dependent phosphatase calcineurin controls the formation of the carma1-Bcl10-Malt1 complex during T cell receptor-induced NF-kB activation. J Biol Chem 2011;286(9):7522–34.Schmitz R., Hansmann M.-L., Bohle V., Martin-Subero J.I., Hartmann S., Mechtersheimer G. et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009;206(5):981–9.Yu X., Li W., Deng Q., Liu H., Wang X., Hu H. et al. MYD88 L265P elicits mutation-specific ubiquitination to drive NF-kB activation and lymphomagenesis. Blood 2021;137(12):1615–27.Knies N., Alankus B., Weilemann A., Tzankov A., Brunner K., Ruff T. et al. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-kB and JNK activation. Proc Natl Acad Sci U S A 2015;112(52): E7230–8.Turvey S.E., Durandy A., Fischer A., Fung S.-Y., Geha R.S., Gewies A. et al. The CARD11-BCL10-MALT1 (CBM) signalosome complex: stepping into the limelight of human primary immunodeficiency. J Allergy Clin Immunol 2014;134(2): 276–84.Rossi D., Deaglio S., Dominguez-Sola D., Rasi S., Vaisitti T., Agostinelli C. et al. Alteration of BIRC3 and multiple other NF-kB pathway genes in splenic marginal zone lymphoma. Blood 2011;118(18):4930–34.Li M.Y., Chong L.C., Duns G., Lytle A., Woolcock B., Jiang A. et al. TRAF3 loss-of-function reveals the noncanonical NF-kB pathway as a therapeutic target in diffuse large B cell lymphoma. Proc Natl Acad Sci 2024;121(18):e2320421121.Lue J.K., Luttwak E., Rivas-Delgado A., Irawan H., Boardman A., Caron P.C. et al. Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes. Blood Cancer J 2024;14(1):178.Li S., Lin P., Young K.H., Kanagal-Shamanna R., Cameron Yin C., Medeiros L.J. MYC/BCL2 double-Hit high-grade B-cell lymphoma. Adv Anat Pathol 2013;20(5):315.Berhan A., Almaw A., Damtie S., Solomon Y. Diffuse large B cell lymphoma (DLBCL): epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: narrative review. Discov Oncol 2025;16(1):184.Dunleavy K., Grant C., Wilson W.H. Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma. Ther Adv Hematol 2013;4(1):43–57.Li W. Pathogenesis and pathology of pediatric lymphoma. In: Lymphoma. By ed. Gallamini A., Juweid M. Brisbane. AU: Exon Publications, 2021.Schmitz R., Wright G.W., Wei Huang D., Johnson C.A., Phelan J.D., Wang J.Q. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 2018;378(15):1396–407.Reber R., Banz Y., Garamvölgyi E., Perren A., Novak U. Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry: a case series from the Inselspital, Bern, and a critical appraisal of this determination in Switzerland. Swiss Med Wkly 2013;143:w13748.Wn Najmiyah W.A.W., Azlan H., Faezahtul A.H. Classifying DLBCL according cell of origin using Hans algorithm and its association with clinicopathological parameters: a single centre experience. Med J Malaysia 2020;75(2):98–102.Deffenbacher K.E., Iqbal J., Sanger W., Shen Y., Lachel C., Liu Z. et al. Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood 2012;119(16):3757–66.Shimkus G., Nonaka T. Molecular classification and therapeutics in diffuse large B-cell lymphoma. Front Mol Biosci 2023;10.Miyaoka M., Yukie Kikuti Y., Carreras J., Ito A., Ikoma H., Tomita S. et al. Copy number alteration and mutational profile of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, diffuse large B-cell lymphoma with MYC-rearrangement, and diffuse large B-cell lymphoma with MYC-cluster amplification. Cancers (Basel) 2022;14(23):5849.Wright G.W., Wei Huang D., Phelan J.D., Coulibaly Z.A., Roulland S., Young R.M. et al. A probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell 2020;37(4):551–68.e14.Huibers M., Abla O., Andrés M., Balagué O., Beishuizen A., Carraro E. et al. Large B-cell lymphoma-IRF4+ in children and young people: time to reduce chemotherapy in a rare malignant mature B-cell neoplasm? Blood Adv 2024;8(6):1509–14.Jiang X.-N., Yu F., Xue T., Xia Q.-X., Bai Q.-M., Yu B.-H. et al. IRF4 rearrangement may predict favorable prognosis in children and young adults with primary head and neck large B-cell lymphoma. Cancer Med 2023;12(9):10684–93.Kim D.H., Li S., Garces S., Xu J. Large B-cell lymphoma with IRF4 rearrangement and follicular pattern: a differential diagnosis of follicular lymphoma. Human Pathol Rep 2022;27:300602.Martelli M., Ferreri A.J.M., Johnson P. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol 2008;68(3).Donzel M., Pesce F., Trecourt A., Groussel R., Bachy E., Ghesquières H. et al. Molecular characterization of primary mediastinal large B-cell lymphomas. Cancers (Basel) 2023;15(19):4866.Ahmed Z., Saadat Afridi S., Shahid Z., Zamani Z., Rehman S., Aiman W. et al. Primary mediastinal B-Cell lymphoma: a 2021 update on genetics, diagnosis, and novel therapeutics. Clin Lymphoma Myeloma Leuk 2021;21(11):e865–75.Camus V., Viailly P.-J., Drieux F., Veresezan E.-L., Sesques P., Haioun C. et al. High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma. Blood Adv 2023;7(23):7331–45.Steidl C., Gascoyne R.D. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011;118(10):2659–69.Zhang C., Wang Z., Ji Q., Li Q. Histone demethylase JMJD2C: epigenetic regulators in tumors. Oncotarget 2017;8(53):91723–33.Chen H., Pan T., He Y., Zeng R., Li Y., Yi L. et al. Primary mediastinal B-Cell lymphoma: novel precision therapies and future directions. Front Oncol 2021;11:654854.Sharlai A.S., Volchkov E.V., Abramov D.S., Sidorov I.V., Baranova M.A., Myakova N.V., Konovalov D.M. An improved algorithm for genetic diagnostics of aggressive B-cell lymphomas in pediatric oncohematology: the experience of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Arch Pathol 2026;87(1):5–10. [Article in Russian].